Research progress of TACE combined with traditional Chinese medicine in the treatment of unresectable hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-5782.2019.02.009

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China, and most patients with advanced HCC have lost the opportunity of surgical resection. At this time, TACE is by far the preferred treatment. It has better clinical efficacy, but its adverse reactions are also the problem that clinicians must face. Traditional Chinese medicine (TCM) is mild in nature and has few toxic and side effect, and it can reduce the dosage of chemotherapy drugs and improve the immunity of the body. Therefore, TACE combined with TCM for the treatment of HCC has been gradually promoted by clinicians. The purpose of this paper is to review the application and advantages of TACE combined with TCM such as Kanglaite, Elemene, Huaier and Ganfule.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Traditional chinese medicine, Kanglaite, Elemene, Huaier, Ganfule

Yuan Yao, Jianjian Chen, Xueliang Zhou, Dechao Jiao, Xinwei Han. Research progress of TACE combined with traditional Chinese medicine in the treatment of unresectable hepatocellular carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(02): 130-134.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2019.02.009

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2019/V07/I02/130

References 43

[1]	Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy[J]. Pharmacol Ther，2017，173:106-117.
[2]	Singh S, Singh PP, Roberts LR，et al. Chemopreventive strategies in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol，2014，11(1):45-54.
[3]	Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma[J]. Korean J Radiol，2009，10(5):425-434.
[4]	邱力戈，梁若斯，李勇，等.HepaSphere载药微球与碘油化疗栓塞大肝癌的不良反应比较[J].中华介入放射学电子杂志，2018，6(2):99-103.
[5]	苏莹莹，刘莹钰，张扬雨，等. 9种中药注射剂联合肝动脉插管化疗栓塞术治疗原发性肝癌的网状Meta分析[J].吉林大学学报（医学版），2016，42(6):1126-1131.
[6]	李戈，赵晨，思金华，等. 19种中药注射剂联合TACE治疗中晚期肝细胞癌的网状Meta分析[J].兰州大学学报（医学版），2016，42(3):57-63,72.
[7]	石芳毓，娄丽丽，谢吻，等.中药注射剂联合肝动脉插管栓塞化疗术治疗肝癌的网状Meta分析[J].中国实验方剂学杂志，2016，22(10):180-187.
[8]	Long ZX, Wang B, Tao D，et al. Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma[J]. Oncol Lett，2015，10(1):523-527.
[9]	Cai B, Ma LM, Nong SJ，et al. Β-elemene induced anticancer effect in bladder cancer through upregulation of PTEN and suppression of AKT phosphorylation[J]. Oncol Lett，2018，16(5):6019-6025.
[10]	Hu TL, Gao Y. Β-elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway[J]. Biomed Pharmacother，2018，106:1557-1562.
[11]	Wu BQ, Jiang Y, Zhu F，et al. Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703[J]. Oncol Lett，2016，11(4):2545-2551.
[12]	Fu F, Wan YD, Wu T，et al. Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: A meta-analysis[J]. J Cancer Res Ther，2014，10(Suppl 1):38-41.
[13]	Huang XL, Qin JJ, Lu S. Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantation-induced tumor growth[J]. Mol Med Rep，2014，10(4):2153-2159.
[14]	吴进录.康莱特注射液联合介入化疗治疗中晚期肝癌的临床观察[J].中国民间疗法，2015，23(12):60-61.
[15]	谢和平，李跃，王凤林，等.康莱特注射液联合肝动脉化疗栓塞术治疗原发性肝癌临床疗效[J].中成药，2018，40(12):2821-2823.
[16]	汪有锦.康莱特在肝癌介入治疗中的作用.中国中西医结合学会医学影像专业委员会第十五次全国学术大会[C].中国上海，2017.
[17]	张宜江，曹继华，徐兴东，等.康莱特联合介入化疗治疗原发性肝癌的临床研究[J].肿瘤药学，2017，7(1):104-108.
[18]	路大鹏，王玉强，赵卫林，等.康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J].世界临床医学，2017，11(5):70,72.
[19]	袁琴，王虚实，王君钰，等.榄香烯乳注射液对原发性肝癌患者免疫功能的影响[J].癌症进展，2016，14(7):664-666,670.
[20]	Wang QT, Zhang ZL, Xiong H，et al. Evaluation of the efficacy and safety of elemene in treating malignant pleural effusion caused by tumors: A PRISMA guided meta-analysis[J]. Medicine （Baltimore），2018，97(44):e12542.
[21]	Wu ZB, Wang T, Zhang YM，et al. Anticancer effects of β-elemene with hyperthermia in lung cancer cells[J]. Exp Ther Med，2017，13(6):3153-3157.
[22]	Mao YQ, Zhang JL, Hou L，et al. The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma HepG2 cells[J]. Chin J Cancer Res，2013，25(6):770-776.
[23]	杨宇辉，吴清艺，黄印强，等.榄香烯联合肝动脉化疗栓塞治疗中晚期肝癌[J].中国卫生标准管理，2017，8(18):102-103.
[24]	王小璞，赵昌林，郑丹如.榄香烯注射液联合TACE治疗晚期原发性肝癌疗效观察[J].新中医，2017，49(5):87-90.
[25]	陈德连，江会红.榄香烯联合介入治疗中晚期肝癌患者的近期疗效[J].广州中医药大学学报，2016，33(1):27-30.
[26]	Zhao GS, Liu Y, Zhang Q，et al. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: Safety and efficacy[J]. Medicine（Baltimore），2017，96(29):e7589.
[27]	Zhang CS, Zhang JL, Li X，et al. Huaier aqueous extract induces hepatocellular carcinoma cells arrest in S phase via JNK signaling pathway[J]. Evid Based Complement Alternat Med，2015，2015:171356.
[28]	Bao HD, Liu P, Jiang K，et al. Huaier polysaccharide induces apoptosis in hepatocellular carcinoma cells through p38 MAPK[J]. Oncol Lett，2016，12(2):1058-1066.
[29]	Zheng JS, Li C, Wu X，et al. Huaier polysaccharides suppresses hepatocarcinoma MHCC97-H cell metastasis via inactivation of EMT and AEG-1 pathway[J]. Int J Biol Macromol，2014，64:106-110.
[30]	Zheng JS, Li C, Wu X，et al. Astrocyte elevated gene-1（AEG-1）shRNA sensitizes Huaier polysaccharide（HP）-induced anti-metastatic potency via inactivating downstream P13K/Akt pathway as well as augmenting cell-mediated immune response[J]. Tumour Biol，2014，35(5):4219-4224.
[31]	Hu ZD, Yang AL, Su GZ，et al. Huaier restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV[J]. Sci Rep，2016，6:31298.
[32]	冯惠岗，梁奇伟，郭惠庄，等.甘草酸二铵联合槐耳颗粒治疗肝癌TACE术后栓塞综合征临床观察[J].中华介入放射学电子杂志，2016，4(4):197-201.
[33]	董德硕，刘兆玉.槐耳颗粒联合经肝动脉化疗栓塞术治疗肝细胞癌的研究进展[J].临床肝胆病杂志，2017，33(10):2021-2024.
[34]	董德硕，刘兆玉.基于真实世界肝动脉化疗栓塞术联合槐耳颗粒治疗肝细胞癌的临床研究[J].现代肿瘤医学，2018，26(5):741-746.
[35]	华向东，尚海，何忠野，等.槐耳颗粒联合经导管肝动脉化疗栓塞在原发性肝癌伴微血管侵犯根治术后的疗效分析[J].中国普外基础与临床杂志，2016，23(8):982-986.
[36]	尹剑，郭安红.肝动脉化疗栓塞联合肝复乐胶囊治疗原发性肝癌疗效及对血浆VEGF和内毒素的影响[J].现代中西医结合杂志，2018，27(24):2696-2699.
[37]	张继万，周建丽，张晓芳，等. Peg-IFN-α2a联合肝复乐胶囊对HbeAg阳性慢性乙型肝炎抗肝纤维化的疗效[J].武警医学，2017，28(3):257-260.
[38]	曹付春，韩雅莉，陈冰，等.地鳖纤溶蛋白对人脐静脉内皮细胞、肺癌、乳腺癌细胞VEGF和bFGF表达的影响[J].时珍国医国药，2011，22(8):1827-1829.
[39]	郝明志，陈武进，林海澜，等.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].中南药学，2013，11(02):147-150.
[40]	周德江，何胜，翁敏.口服肝复乐联合经皮肝动脉栓塞化疗治疗中晚期原发性肝癌42例临床观察[J].医药前沿，2011，1(24):10-11.
[41]	Jiang YW, Yuan Q, Huang AB，et al. The synergistic mechanism of pemetrexed followed by kanglaite was due to KLT subsequently inhibiting the pemetrexed-activated MAPK signaling pathway[J]. Clin Lab，2015，61(10):1353-1363.
[42]	Liu Y, Zhang W, Wang XJ，et al. Antitumor effect of Kanglaite? injection in human pancreatic cancer xenografts[J]. BMC Complement Altern Med，2014，14:228.
[43]	Du X, Ye H, Zhang C，et al. Effect of kanglaite on rat cytochrome P450[J]. Pharm Biol，2014，53(7):995-1001.

Please choose a citation manager

Content to export